84 related articles for article (PubMed ID: 21632983)
1. Rituximab's new therapeutic target: the podocyte actin cytoskeleton.
Chan AC
Sci Transl Med; 2011 Jun; 3(85):85ps21. PubMed ID: 21632983
[TBL] [Abstract][Full Text] [Related]
2. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.
Fornoni A; Sageshima J; Wei C; Merscher-Gomez S; Aguillon-Prada R; Jauregui AN; Li J; Mattiazzi A; Ciancio G; Chen L; Zilleruelo G; Abitbol C; Chandar J; Seeherunvong W; Ricordi C; Ikehata M; Rastaldi MP; Reiser J; Burke GW
Sci Transl Med; 2011 Jun; 3(85):85ra46. PubMed ID: 21632984
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation.
Tsagalis G; Psimenou E; Nakopoulou L; Laggouranis A
Artif Organs; 2011 Apr; 35(4):420-5. PubMed ID: 20637013
[TBL] [Abstract][Full Text] [Related]
4. Different targets for treating focal segmental glomerular sclerosis.
Coppo R
Contrib Nephrol; 2013; 181():84-90. PubMed ID: 23689570
[TBL] [Abstract][Full Text] [Related]
5. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats.
Celik Y; Celik F
Transl Res; 2006 Jul; 148(1):46. PubMed ID: 16887498
[No Abstract] [Full Text] [Related]
6. A case of recurrent focal segmental glomerulosclerosis (FSGS) involving massive proteinuria (>50 g/day) immediately after renal transplantation.
Okamoto M; Koshino K; Sakai K; Nobori S; Matsuyama M; Ushigome H; Okajima H; Masuzawa N; Yoshimura N
Clin Transplant; 2011 Jul; 25 Suppl 23():53-8. PubMed ID: 21623916
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of recurrent focal segmental glomerulosclerosis after renal transplantation by lymphocytapheresis and rituximab.
Shimizu M; Kitagawa K; Nishio S; Yokoyama T; Furuichi K; Ohta K; Wada T; Yachie A
Transpl Int; 2010 Sep; 23(9):e53-5. PubMed ID: 20536913
[No Abstract] [Full Text] [Related]
8. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats.
Chen CA; Hwang JC; Guh JY; Chang JM; Lai YH; Chen HC
J Lab Clin Med; 2006 Feb; 147(2):74-82. PubMed ID: 16459165
[TBL] [Abstract][Full Text] [Related]
9. TRPC6 - a new podocyte gene involved in focal segmental glomerulosclerosis.
Kriz W
Trends Mol Med; 2005 Dec; 11(12):527-30. PubMed ID: 16290061
[TBL] [Abstract][Full Text] [Related]
10. Bigenic heterozygosity and the development of steroid-resistant focal segmental glomerulosclerosis.
Löwik M; Levtchenko E; Westra D; Groenen P; Steenbergen E; Weening J; Lilien M; Monnens L; van den Heuvel L
Nephrol Dial Transplant; 2008 Oct; 23(10):3146-51. PubMed ID: 18443213
[TBL] [Abstract][Full Text] [Related]
11. Ultrastructural features and expression of cytoskeleton proteins of podocyte from patients with minimal change disease and focal segmental glomerulosclerosis.
Shi SF; Wang SX; Zhang YK; Zhao MH; Zou WZ
Ren Fail; 2008; 30(5):477-83. PubMed ID: 18569926
[TBL] [Abstract][Full Text] [Related]
12. Krüppel-Like Factor 15 Mediates Glucocorticoid-Induced Restoration of Podocyte Differentiation Markers.
Mallipattu SK; Guo Y; Revelo MP; Roa-Peña L; Miller T; Ling J; Shankland SJ; Bialkowska AB; Ly V; Estrada C; Jain MK; Lu Y; Ma'ayan A; Mehrotra A; Yacoub R; Nord EP; Woroniecki RP; Yang VW; He JC
J Am Soc Nephrol; 2017 Jan; 28(1):166-184. PubMed ID: 27288011
[TBL] [Abstract][Full Text] [Related]
13. IGF-binding protein-3 modulates TGF-beta/BMP-signaling in glomerular podocytes.
Peters I; Tossidou I; Achenbach J; Woroniecki R; Mengel M; Park JK; Paschy M; de Groot K; Haller H; Schiffer M
J Am Soc Nephrol; 2006 Jun; 17(6):1644-56. PubMed ID: 16672319
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of galectin-1 in renal biopsy specimens of children and its possible role in proteinuric glomerulopathies.
Ostalska-Nowicka D; Zachwieja J; Nowicki M; Kaczmarek E; Siwińska A; Witt M
Histopathology; 2007 Oct; 51(4):468-76. PubMed ID: 17880528
[TBL] [Abstract][Full Text] [Related]
15. The spectrum of focal segmental glomerulosclerosis: new insights.
D'Agati VD
Curr Opin Nephrol Hypertens; 2008 May; 17(3):271-81. PubMed ID: 18408478
[TBL] [Abstract][Full Text] [Related]
16. Effects of TGF-beta on podocyte growth and disease progression in proliferative podocytopathies.
Lee HS; Song CY
Kidney Blood Press Res; 2010; 33(1):24-9. PubMed ID: 20185928
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature.
Peters HP; van de Kar NC; Wetzels JF
Neth J Med; 2008 Nov; 66(10):408-15. PubMed ID: 19011266
[TBL] [Abstract][Full Text] [Related]
18. Direct effect of plasma permeability factors from patients with idiopatic FSGS on nephrin and podocin expression in human podocytes.
Doublier S; Musante L; Lupia E; Candiano G; Spatola T; Caridi G; Zennaro C; Carraro M; Ghiggeri GM; Camussi G
Int J Mol Med; 2005 Jul; 16(1):49-58. PubMed ID: 15942677
[TBL] [Abstract][Full Text] [Related]
19. Immunoexpression of podocyte-associated proteins in acquired human glomerulopathies with nephrotic syndrome.
Wagrowska-Danilewicz M; Stasikowska O; Danilewicz M
Pol J Pathol; 2006; 57(1):17-21. PubMed ID: 16739878
[TBL] [Abstract][Full Text] [Related]
20. Parietal epithelia cells in the urine as a marker of disease activity in glomerular diseases.
Achenbach J; Mengel M; Tossidou I; Peters I; Park JK; Haubitz M; Ehrich JH; Haller H; Schiffer M
Nephrol Dial Transplant; 2008 Oct; 23(10):3138-45. PubMed ID: 18458033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
